In this “Voices on Cancer” post, stage 4 esophageal cancer survivor Dana Deighton shares what it was like receiving an advanced diagnosis, how she advocated for herself during treatment, and how her diagnosis led her to a career in patient and research advocacy.
In this podcast, Dr. Frank Penedo interviews esophageal cancer survivor Rachael Kearney about her experience being diagnosed with cancer, how she coped with side effects from treatment, and her advice for sharing your cancer story.
Survivor Rachael Kearney describes what it was like being diagnosed and treated for esophageal cancer, how she adjusted to the life changes her treatment brought, and how her cancer diagnosis led her to finding a new life purpose.
In this podcast, Cancer.Net Associate Editors discuss new research presented at the 2021 ASCO Annual Meeting on brain tumors, esophageal cancer, and colorectal cancer.
The ASCO Annual Meeting begins on June 4, and here is some of the notable research that will be presented. Topics include combined immunotherapy for esophageal cancer, targeted radiation for mCRPC, olaparib for HER2-negative breast cancer, adjuvant chemotherapy for cervical cancer, pembrolizumab for kidney cancer, and toripalimab for nasopharyngeal cancer.
ASCO’s 2021 Advance of the Year highlights how progress in the treatment of gastrointestinal (GI) cancers is driven by molecular testing of tumors.
Cancer.Net Associate Editors explain research presented at the 2019 ASCO Annual Meeting, including new research in colon cancer, gastric cancer, pancreatic cancer, and leukemia.
The ASCO Annual Meeting is where many new cancer research findings are announced. Today’s key research highlights include treatment advances for advanced lung cancer, stomach cancer, gastroesophageal junction cancer, and breast cancer.
Read research highlights that will be presented at the 2019 ASCO Annual Meeting, covering low-fat diets and risk of breast cancer death, chemotherapy for older adults with esophageal cancer, targeted therapy for those at risk for multiple myeloma, the rate of genetic changes in childhood cancers, and a new targeted therapy for childhood central nervous system tumors.
